The Mounjaro titration schedule: what the evidence says about stepping up your dose

What the SURMOUNT programme told us about dose and weight loss

The SURMOUNT-1 trial, published in the New England Journal of Medicine, tested tirzepatide at 5 mg, 10 mg, and 15 mg maintenance doses across more than 2,500 adults with obesity over 72 weeks. The headline finding (average body-weight reductions of roughly 15% at 5 mg, around 20% at 10 mg, and approximately 20–21% at 15 mg) was not achieved overnight. Every participant in the trial followed the same graduated entry path, spending four weeks at each preceding dose before arriving at their maintenance level. The structured ramp-up was not bureaucratic caution; it was the design feature that kept tolerability high enough for people to stay in the study and reach meaningful doses.

That architecture is now reflected in the UK licence. If you want a clear overview of how each step fits together, our Mounjaro dose schedule page sets out the full progression and what to expect at each stage. The schedule exists because the gastrointestinal side effects of tirzepatide (nausea, changes in bowel habit, indigestion) are most pronounced when the dose rises quickly. Spreading increases across four-week intervals gives the gut time to adapt. In the SURMOUNT programme, gastrointestinal events were most common in the weeks immediately after a dose step, then settled. Slowing the titration when needed was permitted in the trial protocols, and the same flexibility sits inside the licensed prescribing framework.

One practical note our prescribers raise regularly: the 2.5 mg starter pen does a specific job. Its purpose is adjustment, not treatment. Expecting significant weight loss at this stage sets up unnecessary disappointment, the therapeutic doses start at 5 mg and above, which is also why our 5 mg Mounjaro page covers what that first full-dose step typically feels like.

The six doses in sequence: what changes at each step

The full licensed schedule runs: 2.5 mg (weeks 1–4) → 5 mg (weeks 5–8) → 7.5 mg (weeks 9–12) → 10 mg (weeks 13–16) → 12.5 mg (weeks 17–20) → 15 mg (week 21 onward). Each arrow represents a dose increase that should only happen after four weeks at the preceding level, and only when your prescriber is satisfied with how you have been tolerating treatment.

Not every person will complete the full ladder. Some people find that 10 mg provides excellent appetite suppression with manageable side effects, and that moving to 12.5 mg adds little benefit but more nausea. Staying at the highest well-tolerated dose is entirely consistent with the licensed approach. The SmPC is clear that 15 mg is the ceiling, not an expectation. Equally, some people move through the lower steps quickly and comfortably, reaching 15 mg around month five with minimal disruption.

What the schedule does not build in is any automatic progression. At nume (at num) at a clinical service like ours, each dose increase requires a prescriber to review your current situation before confirming the next pen. That review considers how much weight you have lost, whether side effects have settled, and whether there is any new clinical information. Details on how the 10 mg step specifically fits into the sequence are on our Mounjaro 10 mg page, which covers what to expect when you reach that point.

When titration slows, pauses, or goes in reverse

The most common reason for slowing a titration is persistent nausea or vomiting after a dose increase. If GI symptoms remain disruptive beyond two weeks at a new dose, the licensed option is to extend the time at that level rather than push upward. In some cases, returning temporarily to the previous dose is appropriate, always under prescriber guidance, never as a unilateral decision. Our page on how Mounjaro titration works in practice covers these adjustment scenarios in more detail.

There is also the question of what happens if someone wants to stop treatment altogether. Tirzepatide is not stopped abruptly for safety reasons in the way some medicines are, but there is a clinical rationale for tapering rather than stopping cold, particularly at higher doses. The guidance on titrating off tirzepatide explains what that process involves and why it is a conversation to have with your prescriber before making any changes.

Storage routine matters more during a slow titration, because pens may sit in the fridge longer than usual, keep each pen in the fridge door away from the freezer section, and check the expiry before any injection. Room-temperature windows exist but the exact duration is set out in the Patient Information Leaflet rather than here, because it is dose-specific information your prescriber and pharmacist should confirm for your pen.

Private titration support versus going it alone: what clinical oversight adds

One thing the trial data cannot replicate is the real-world experience of managing a titration without regular clinical contact. In SURMOUNT-1, participants had structured check-ins and protocol oversight. Most people accessing Mounjaro privately do not have weekly clinical contact, which is why the quality of support between doses matters.

Cost is a reasonable question here. Treatment across multiple dose steps adds up, and understanding the full picture of what private prescribing costs at each level is worth doing before you start. Our Mounjaro pricing page sets out how costs are structured across the dose range. At nume, there are no hidden fees layered on top (consultation, prescription, and next-working-day tracked delivery are included) and every repeat order is reviewed by a GPhC-registered prescriber before dispatch, not processed automatically.

If you are at any point unsure whether a dose increase is right for you, or if a side effect has you wondering whether to stay put or step back, that is exactly the kind of question to bring to a prescriber rather than answer alone. You can explore our weight-loss treatment options or speak to our prescribers about starting or continuing a tirzepatide titration schedule with proper clinical support.